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Background: Determining eligibility for a kidney transplant is an important decision. Practice guidelines define
contraindications to transplantation; however many are not evidence based. Canadian guidelines recommend that
patients unlikely to survive the wait period not be evaluated. The purpose of this study was to evaluate what
proportion of patients with a contraindication would survive the wait time.
Methods: Consecutive incident dialysis patients (January 2006 to December 2012) with a contraindication, defined
using Canadian guidelines, were studied. Mortality rates were determined for each individual contraindication.
Theoretical survival to the median wait time to transplantation was calculated.
Results: Of 746 incident patients, 435 (58 %) were deemed to have a contraindication at dialysis start. Nearly 80 %
had a contraindication with a high mortality rate (dementia, multisystem disease, etc.). Patients with high mortality
rates were less likely to survive the wait list than be transplanted. Patients with non-adherence, obesity, and
potentially reversible disease had relatively low mortality rates, were more likely to survive, and possibly be
transplanted at a time with the prospect of a better outcome.
Conclusions: This study gives some credence that many patients with a contraindication are not likely to benefit.
A better framework of defining contraindications is needed to allow better decision-making.
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Eligibility for a kidney transplant is an important area of
concern for patients with end-stage renal disease
(ESRD). In a recent publication, Canadian Blood Ser-
vices demanded that organ donation and transplantation
services be fair, accountable, and transparent with regard
to eligibility for the wait list and allocation of organs [1].
A recent review of worldwide practice showed consider-
able variability with regard to eligibility criteria and an
overall concern for a lack of evidence-based decisions
[2]. There is evidence that access to the list is associated
with age, health literacy, race/ethnicity, socioeconomic
status, co-morbidity, and region [3–10]. Many of the
studies use large administrative datasets but these do
not take into account the specific reasons for non-
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creativecommons.org/publicdomain/zero/1.0/The Canadian Society of Transplantation set out eligi-
bility criteria in 2005 [11]. These were mostly opinion
based and have not been tested empirically. The ration-
ale behind the definition of a contraindication to trans-
plantation is variable. For example, immunosuppression
in patients with active infection or cancer may cause
greater harm. Some contraindications are potentially re-
versible (non-adherence, active kidney disease, etc.), and
a delayed period of time might allow for a better relative
outcome. Other conditions may not be true contraindi-
cations but rather may result in only marginal benefit
for the patient (for example, transplanting patients with
a projected short life expectancy).
A randomized control trial to test which contraindica-
tions result in more harm than benefit after transplant-
ation would be required to provide high-quality evidence
but is impractical if not impossible. It is likely that many
not referred or even those with relative contraindications
would benefit if there were a larger pool of available or-
gans. It is also important to recognize that some patientsticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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may take a year or more before transplantation confers a
survival advantage compared to waiting on the trans-
plant list. The time to equal survival is dependent on the
organ type, patient baseline mortality rate, and duration
and magnitude of the increased risk early after the trans-
plant procedure and start of immunosuppression [12].
One of the principles included in the Canadian eligibil-
ity document was that patients unlikely to survive the
wait period not be evaluated [11]. Although low prob-
ability of surviving the wait period is not a contraindica-
tion to transplantation, it does address the issue of
efficiency and whether resources should be used to
evaluate patients who are not likely to benefit. The pur-
pose of this study was to determine, based on the spe-
cific contraindication at the time of dialysis, what
proportion would likely experience ‘no benefit’ from
transplantation (as defined by death on the waitlist) or
would potentially benefit (proportion surviving wait time
and living beyond time of equal survival after transplant-
ation) had they been listed and eligible for a kidney
transplant despite their health status.
Methods
Our center (Capital Health Authority) provides pre-dialysis
and ESRD care including transplantation to an overall popu-
lation of approximately 800,000 individuals from mainland
Nova Scotia. The population sampled was a retrospectively
analyzed cohort of all consecutive incident dialysis patients
from January 2006 to December 2012 at this center. The
sample contained 437 patients from a previous publication
and an additional 309 patients (March 2011 to December
2012) [13]. Patients with a failed transplant were also
considered in this analysis. The study was approved by our
local research board (Capital Health Research Ethics Board).
As described in an earlier publication, eligibility for a
kidney transplant was determined based on Canadian So-
ciety of Transplantation criteria as interpreted by the au-
thors [13]. Categories of contraindication included
dementia, multisystem disease (two or more contraindica-
tions), cancer, pulmonary disease (COPD), congestive
heart failure (CHF), cardiovascular disease (CVD, includ-
ing peripheral vascular disease and stroke), active kidney
disease, active infection, active gastrointestinal (GI) issues
(such as bleeding), obesity (body mass index (BMI) >40
kg/m2), non-adherence, and patient refusal. Patients were
followed until June 2014. Electronic hospital records were
used to identify contraindications and comorbidities
(which were not necessarily contraindications), calculate
the Charlson comorbidity index [13], and collect labora-
tory values at the start of dialysis [14]. This analysis was
based on characterization at initiation of dialysis. However,
if a contraindication was reversible and the patient was
transplanted, the subject was still considered within thecontraindication group but survival was censored at the
time of transplantation.
To calculate the proportion that died on the wait list,
we used median Canadian National time to transplant-
ation data [15]. Many but not all centers require a pa-
tient to be on dialysis before listing. In this analysis, time
zero was the start of dialysis rather than the time of pre-
emptive wait listing. Since there is considerable variation
between provinces, the shortest and longest median time
were also analyzed. The Canadian National median time to
transplantation is 1382 days (3.79 years) whereas the range
among the provinces varied from shortest in Saskatchewan
at 882 days (2.41 years) to the longest in British Columbia
at 1954 days (5.34 years). Other provinces and their wait
times were as follows: Alberta 1265 days, Ontario 1598
days, Quebec 1028 days, Manitoba 1861 days, and Atlantic
Canada (including Nova Scotia) 981 days. The proportion
that survive to transplantation was determined from the
logarithmic survival function defined by proportion
alive = exp^(-MR*t), where MR is mortality rate and t is
time. In a sensitivity analysis, the proportion that survived
was estimated by examining the Kaplan-Meier survival
curves for the different groups of patients and visual com-
parison of the logarithmic survival function and Kaplan-
Meier survival curves for differences in true and predicted
cumulative survival. To estimate the proportion who sur-
vived to net benefit, the total time included median wait
time and the time to equal survival. The time to equal sur-
vival after transplantation can vary from 120 days to over
750 days depending on the organ used (standard com-
pared to expanded criteria) and patient mortality rate. As
a conservative estimate, patients with a mortality rate of
<20 deaths per 100 patient years were assumed to have a
time of equal survival of 180 (0.5 years) days and those
with a mortality >20 deaths per 100 patient years were as-
sumed to have a time of equal survival of 365 (1 year) days
[12]. Although it is likely that the time to equal survival
might be considerably longer than 1 year for many of our
patients with contraindications, there was limited pub-
lished data to justify lengthening this time. If longer times
are likely, then the proportion that would benefit from
transplantation would be reduced.
Data are presented as means and standard deviation, me-
dian, and inter-quartile range or percentages where appro-
priate. Crude mortality rates with 95 % confidence intervals
(CI) were determined by the number of deaths divided by
years of exposure. Patient survival was examined by the
Kaplan-Meier product limit method. A p value of <0.05
was the threshold for statistical significance. Statistical ana-
lysis was performed using Stata Version 12.0 (Texas, USA).
Results
There were 746 adult patients that started dialysis (median
follow-up of 2.13 (0.96, 3.6) years). Of these, 435 (58 %)
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ESRD treatment. Table 1 shows the characteristics and se-
lected comorbidities of patients with a contraindication.
There were 257 deaths (59 % of this cohort) with a crude
mortality rate of 22.4 (95 % CI 19.7–25.1) deaths per 100
patient years. Reasons for contraindication, proportion of
subjects within each contraindication category, mortality
rate, probability of waitlist survival, and probability of sur-
vival to net benefit are shown in the Table 2. Nearly 80 %
(78.4 %) of patients were in groups with <50 % probability
of surviving the wait time and 36.6 % of the patients had a
<25 % chance of benefiting from a transplant using the
national median wait time average.
Some of the patients had a contraindication that was
reversible (infection, gastrointestinal bleeding, etc.) or
potentially reversible (obesity and non-adherence). Most
of the patients with multisystem disease, cancer, and car-
diovascular and chronic obstructive pulmonary disease
had conditions that were irreversible. Table 3 shows the
subset of patients that were felt to have irreversible dis-
ease with these conditions. Overall, this group (n = 275)
suffered 206 deaths with a rate of 32 (95 % CI 27.8–
36.6) deaths per 100 patient years. Of the 435 patients
with a contraindication, 106 (24 %) were referred to the
transplant team at some point over their care, 31 (7.1 %)
were actually activated on the wait list after resolution of
their contraindication, and 18 (4.1 %) were transplanted.
Those listed included CVD-6, active kidney disease-5,
non-adherence-8, multisystem-3, infection-2, cancer-3,
GI-2, and refused-2. For example, patients with prior
cancer that was in remission for the recommended wait
time, corrected cardiovascular disease, improved adher-
ence, resolution of infection, and correction of GI bleed-
ing were activated.Table 1 Patient characteristics and selected co-morbidities
Contraindication Eligib
(n = 435) (n = 2
Age, years 65 ± 18 50 ±
Male, n (%) 269 (62) 134 (6
Diabetes mellitus, n (%) 188 (43) 50 (23
Co-morbidities
IHD, n (%) 181 (41) 29 (13
CHF, n (%) 137 (31) 20 (9)
COPD, n (%) 91 (21) 17 (8)
BMI, kg/m2 30 ± 9 29 ±
Hemoglobin, g/L 96 ± 17 103 ±
eGFR (ml/min/1.73 m2) 8.5 ± 3.8 8.2 ±
Albumin, g/L 30 ± 6 35 ±
Charlson comorbidity index 5.4 ± 2.4 3.0 ±
Failed transplant, n (%) 32 (7) 14 (7)
aContinuous values are reported as mean ± standard deviationMost survival rates approached a logarithmic decay
(Fig. 1 for cancer and Fig. 2 cardiovascular disease). The
differences between cumulative survival as evaluated by
the Kaplan-Meier method and logarithmic function were
minimal for most groups. The exception was the group
with active kidney disease as shown in Fig. 3. This group
had a very rapid death rate over the first year followed
by a much lower mortality rate. The probability of wait-
list survival and probability of survival to net benefit
using life table analysis are shown in the supporting in-
formation file.
In the overall cohort of 746 patients, 215 (32 %) were
referred for transplantation and had no contraindication
at the start of dialysis (Table 1). These patients were
younger with few co-morbidities (lower Charlson co-
morbidity index). The survival of this cohort was ex-
tremely high (only 10 deaths) with a crude mortality rate
of 2.0 (95 % CI 1.0–3.7) deaths per 100 patient years
(Fig. 4). Patients with this overall mortality rate were
projected to achieve a survival benefit >90 % of the time.
Table 1 and Figure 4 also show the remaining subset of
96 patients that were eligible but never referred. They
were older with significant comorbidity and had a much
higher overall mortality rate compared to eligible wait-
listed patients (54 deaths, 17.2 deaths per 100 patient
years, 95 % CI 13.2–22.5).
Discussion
Much has recently been written on the principles of eli-
gibility and organ allocation from a community, patient,
and physician perspective [16–19]. Invariably, there are
competing ethical principles that balance fairness, effi-
ciency, and appropriate use of a scare resource. The
aim of this study was to determine if patients with ale and referred Eligible but not referred p value
15) (n = 96)
15 74 ± 9 <0.001
2) 55 (57) 0.63
) 37 (39) <0.001
) 25 (26) <0.001
20 (21) <0.001
23 (24) <0.001
7 29 ± 6 0.038
19 101 ± 16 <0.001
3.3 10.5 ± 13.3 <0.001
6 32 ± 5 <0.001
1.8 4.5 ± 2.0 <0.001
2 (2) 0.163
Table 2 Probability of wait list survival and survival to benefit
Contraindication Number Mean age Deaths Deaths per 100 patient years Probability of surviving Probability of benefit, %
(%) (years) (95 % CI) Wait list, % (provincial range) (provincial range)
Dementia 10 (2) 76 7 49.7 (23.7–104.2) 15 (7, 30) 9 (4, 18)
Multisystem 34 (7.8) 67 28 42.1 (29.1–61.1) 20 (11, 36) 13 (7, 24)
Cancer 74 (17) 68 56 35.9 (27.6–46.7) 26 (15, 42) 18 (10, 30)
CHF 42 (9.6) 69 26 29.7 (20.2–43.7) 32 (21, 49) 24 (15, 36)
Active kidney disease 32 (7.3) 64 18 27.6 (17.3–43.8) 35 (23, 51) 27 (18, 39)
CVD 140 (32) 68 89 22.7 (18.4–27.9) 42 (30, 58) 34 (24, 46)
COPD 10 (2.3) 73 7 20.6 (9.8–43.1) 46 (34, 61) 37 (27, 50)
Infection 11 (2.5) 61 6 16.5 (7.4–36.7) 54 (42, 67) 45 (35, 57)
GI 9 (2) 53 4 14.8 (5.6–39.4) 57 (46, 70) 54 (39, 65)
Refused 13 (2.9) 58 4 8.6 (3.2–23.0) 72 (63, 81) 70 (58, 78)
Obesity 19 (4.3) 57 4 5.4 (2.0–14.4) 82 (75, 88) 80 (71, 86)
Non-adherent 41 (9.4) 50 8 5.1 (2.5–10.2) 82 (76, 88) 80 (73, 86)
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to receive a deceased donor organ. The study shows
that nearly 60 % of patients have a contraindication to
transplantation at the start of dialysis. Most of these
have a high mortality rate and would not survive long
enough to benefit from a kidney transplant, especially
those with an irreversible contraindication. There is
considerable variation in mortality rates among the
contraindication groupings.
The novel aspect of this study was that the reasons for
the contraindications were determined by detailed patient
chart review rather than using association data from ad-
ministrative databases. The analysis did not use age or
Charlson comorbidity burden as criteria for contraindica-
tion. As shown in an earlier study, older patients without
contraindications that are not referred constitute a minor-
ity (<15 %) of incident population and tend to have rela-
tively high mortality rates [14].
Although this study demonstrated that many contrain-
dications were associated with a very low probability of
waitlist survival or probability of surviving to a net bene-
fit, it is important to note that kidney transplantationTable 3 Mortality in patients with permanent contraindications




Dementia 10 76 7 49.7 (23.7–
Multisystem 31 71 28 47.5 (32.8–
Cancer 67 67 54 38.8 (29.7–
CHF 36 68 25 34.8 (23.5–
CVD 121 71 85 26.0 (21.0–
COPD 10 73 7 20.6 (9.8–4was not necessarily a futile option (<1 % benefiting) for
many patients. At what point a condition should be
deemed a contraindication based on likelihood of sur-
vival to benefit is unclear. Some would argue, including
many patients, that any realistic possibility should be
considered. This analysis simply presents an estimate of
this proportion without necessarily making a final judg-
ment. Some centers with long waiting times delay trans-
plant eligibility evaluation until patients have sufficient
wait time. For patients with high mortality contraindica-
tions, most will die prior to evaluation. In centers with
relatively short transplant wait times, it is possible that
more marginal candidates will undergo a transplant
workup that may be prolonged and expensive.
Several groups with relatively low mortality rates de-
serve mention. Patients with obesity were a relatively
small percentage of the cohort (4.3 %) and even smaller
(2.6 %) when considering the entire population. Mortal-
ity rates were low in this group but numerically higher
than waitlisted patients. Given the small numbers, a de-
tailed analysis was not performed. Many registry studies
treat obesity as a contraindication at a BMI >35 mg/kg2r
rs
Probability of surviving
wait list (%) (provincial range)
Probability of benefit (%)
(provincial range)
104.2) 15 (7, 30) 9 (4, 18)
68.7) 16 (8, 31) 10 (5, 20)
50.6) 23 (13, 40) 15 (9, 26)
51.5) 32 (15, 43) 18 (11, 30)
32.1) 43 (25, 53) 29 (20, 41)
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Fig. 1 Cumulative survival for patients with a contraindication to
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Fig. 3 Cumulative survival for patients with a contraindication to
transplantation due to acute kidney injury
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clear whether obesity defined as a BMI >40 mg/kg2 is a
legitimate contraindication [21].
A small percentage (<2 % of total cohort) refused to
be transplanted and were included as a contraindication.
Of the 13 patients, 8 had been referred but most did not
complete their evaluation testing. The majority were
male (69 %) with a mean age of 58. Patient refusals
would not be captured in registry analyses. The causes
of refusal are likely multifactorial and were not evaluated
formally [22].
Non-adherence was also associated with a low mortal-
ity rate and comprised 5.4 % of the total incident popu-
lation. Most of these patients were young. Of this group,
22 of the 41 were eventually referred to the wait list.
Since graft loss and return to dialysis is associated with
an increase in mortality, it could be argued that a trial of
demonstrated adherence in subjects with a low mortality
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Kaplan Meier Curve Exponential Curve
Fig. 2 Cumulative survival for patients with a contraindication to
transplantation due to coronary artery or vascular disease[23]. Since our center dates wait time to dialysis start ra-
ther than to the date of listing, once on the wait list time
has not been lost.
On the other hand, the group with active kidney dis-
ease had a very high mortality rate within the first year
but then mortality rates were very low thereafter. Avoid-
ing this high-risk period seems intuitively obvious for
several reasons, including avoiding the risk of disease oc-
curring in the transplanted kidney and optimizing a pa-
tient’s health status in those with active systemic disease.
As with some of the stated contraindications, outcomes
might be better if the contraindication was reversed be-
fore transplantation.
It should be pointed out that the analysis was likely to
be optimistic in favor of transplantation. We did not
specifically analyze the use of expanded criteria donors
which would be associated with longer times to equal pa-
tient survival [12]. It is also likely that patients with
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Fig. 4 Cumulative survival in groups with a contraindication,
candidates for transplantation and those with no contraindication
but not referred
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If the time to equal survival was 2 years rather than 1 year,
the probability of surviving to benefit would be reduced
and could be estimated by multiplying the values in
Table 2 by exp(-MR). For example, for CHF (MR = 0.297),
the probability of survival to potential benefit would be re-
duced from 24 to 18 %. Prior studies calculating time to
equal survival assume that patients on hold on the wait
list have similar mortality rates to those who are active
[24]. Eliminating hold patients would lengthen the time to
equal survival and reduce the proportion likely to benefit
[25]. Patients with contraindications included those that
were reversible and those that were permanent. Perman-
ent contraindication patients had much higher mortality.
It was difficult to determine the exact timing for reversal of
the contraindication, and analyzing this would introduce
immortal time bias. Therefore, the analysis was based on
the initial assessment of those likely to be permanent.
Some but not all patients with reversible contraindications
were referred. In some cases, a new contraindication devel-
oped in follow-up but this was not formally analyzed.
There are notable limitations to the study. This was a
retrospective single center study, and there may well be
regional variations in practice throughout Canada. There
were relatively small numbers of Black or Native Canadian
patients. All patients had medical coverage. Therefore, our
population differs from the USA. However, the median
time to transplantation in the US currently exceeds 1500
days for most adults [26]. Furthermore, current changes
to the US allocation algorithm will reduce the number of
older patients with co-morbidity from receiving a trans-
plant which would increase wait times [27]. In this study,
no patient was transplanted with an active contraindica-
tion; therefore, it is impossible to know the true risk or
benefit. A better assessment of functional status including
a quantitative scoring of frailty might also identify patients
less likely to benefit. The study was not large enough to
look at specific contraindications within groups (waiting 2
years for renal cell cancer after a cancer compared to 5
years for breast cancer). Given the length of follow-up and
small numbers in some groups, survival was projected ra-
ther than using actual survival by life tables. The results of
Table 2 using life table analysis are shown in the support-
ing information file. Some also would argue that quality of
life was not factored in, but most of this time was spent
on dialysis. Those who survived to transplantation would
have experienced the pain of the operation and lived
through an outpatient recovery time that may have been
complicated and prolonged in this vulnerable population.
These complications would also reduce the perceived ben-
efits of transplantation.
Although formal statistics were not carried out prospect-
ively, about 30 % of decisions required a third party review
to determine whether a patient had a contraindication. Oneimportant area for further study would be a determination
of inter-reviewer reproducibility for the determination of a
contraindication as has been done in other studies [28].
There have been surveys examining attitudes of nephrolo-
gists towards transplant referral using case series but these
have not applied a standard eligibility guideline [29, 30]. In
addition, a several sentence description of a patient does
not substitute for a full patient assessment of all the avail-
able data [28, 29]. A multicentre study evaluating the repro-
ducibility of defining a contraindication with a follow-up
educational tool that allows formal training in assessment
would improve transparency and consistency for wait list
eligibility determination on a national level.
Clearly, even patients with high baseline mortality are
likely to be transplanted if they are listed prior to dialysis
start, have a live donor, or are at centers with very short
wait times. However, many Canadian centers do not list
those not yet on dialysis. Patients with a live donor could
potentially have much greater benefit, particularly if they
are transplanted pre-dialysis before a contraindication
develops. The larger issue is whether patients with in-
creased baseline mortality are at a greater risk of early
harm relative to uncertain later benefit with a transplant
[25]. A significant risk of shortening a frail patient’s life
associated with the transplant surgery and immunosup-
pression is a more compelling ethical rationale for not
listing (do no harm) and certainly more defensible than
either ‘not likely live long enough to be transplanted’ or
‘not likely to derive significant benefit’. Although there
are no guaranteed outcomes, making common sense
judgements with individual patients should prevail while
encouraging further debate and study.
Conclusions
For the most part, the current Canadian practice guide-
line defines contraindications to transplantation in pa-
tients with high mortality and low likelihood of
surviving to transplantation or benefiting from this pro-
cedure. This provides some empirical evidence to a
mostly opinion-based guideline. However, some contra-
indications are not associated with high mortality rates
and are reversible. These patients are in the minority but
are more likely to survive to have their contraindication
reversed and subsequently receive a transplant at a time
with the prospect of a better outcome. A better frame-
work of defining contraindications and larger studies are
needed to provide the granular detail not available in
current registry analyses to allow better decision-making
for clinicians.
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